Defendant

If B does not pay the above fine, 100.

1. On August 2010, when Defendant B intends to sell drugs in the course of operating 501 (State)A of the Songpa-gu Seoul Building, Defendant B obtained permission from the Commissioner of the Korea Food and Drug Administration or filed a report on manufactured and sold items of the “E” products without obtaining permission for manufacturing and selling items of the “E” products from F and sold 12,600 market prices of KRW 22,176,000 among the 6,000 market prices to KRW 10,560,000 among them.

2. The Defendant (State) committed a violation of the Pharmaceutical Affairs Act that sells “E” products without permission for manufacture and sale of drugs, at the time and place of the Defendant’s representative, as a juristic person established for wholesale and import of drugs, and for sale of cosmetics.

Summary of Evidence

1. Defendants’ partial statement

1. Each police suspect interrogation protocol against H, I, and J;

1. Application of Acts and subordinate statutes to investigation reports [report on investigation of products and packaging tagss], investigation reports [report on summary policies and replies to the Ministry of Food and Drug Safety as to the classification of products];

1. Article 97, 93 (1) 10, and 61 (1) 2 of the Pharmaceutical Affairs Act: Defendant B; Articles 93 (1) 10 and 61 (1) 2 of the Pharmaceutical Affairs Act; Selection of a fine, Article 61 (1) 2 of the same Act;

1. Defendant B of detention in a workhouse: It is so decided as per Disposition on the grounds of Articles 70(1) and 69(2) of the Criminal Act or more;